The operation described below was likewise based on the concept that an "outflow block" is one of the major physiologic disorders in cirrhotic ascites, and entails both the treatment of ascites by ...

Background: Ascites and pleural effusion are well recognized complications of pancreatic diseases. Drug therapy of these is limited by high cost, prolonged hospitalization and failure rates ...

Catumaxomab Received a Positive Opinion From the EMA's Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If ...

Treatment can be a little complex but focuses on reducing fluid retention and improving your overall quality of life. The ...

Lindis Biotech has licensed Korjuny (catumaxomab) to Pharmanovia for malignant ascites, offering a targeted immune therapy ...

If approved, Korjuny would become the only drug approved for the specific and cancer-directed treatment of malignant ascites, an abnormal accumulation of fluid in the peritoneal cavity that commonly ...

Not all patients with ascites respond to spironolactone, which is the standard treatment for this condition. However, the multinational HypoCAT study has found that satavaptan, a selective ...

The agreement gives Pharmanovia the exclusive rights to bring to market, catumaxomab, a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for the intraperitoneal treatment of ...

J Gastroenterol Hepatol. 2009;24(9):1494-1503. With the application of molecular approaches, efforts towards measuring the bacterial load using DNA in SBP patients have recently been made ...

Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...

Keep abreast with the latest news related to Ascites there are 14 news items on Ascites that covers updates, breakthroughs and in-depth reports. We provide you with a free downloadable secure ...